Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2021-11-25 Director's Dealing
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Allergy Therapeutics: Granting of Awards
Director's Dealing Classification · 98% confidence The document is identified by the 'RNS Number' header and contains information about the vesting and granting of awards under a Long Term Incentive Plan (LTIP) to directors, including specific share option details and resulting holdings. This type of disclosure, detailing personal share transactions by company directors and executives, directly corresponds to the definition of Director's Dealing. The presence of the RNS distribution boilerplate confirms it is a regulatory announcement, but the specific content points strongly to DIRS over the general RNS fallback.
2021-11-25 English
Result of AGM
AGM Information Classification · 99% confidence The document is explicitly titled 'Result of Annual General Meeting' and details the voting outcomes (For/Against/Withheld) for various resolutions presented at the 2021 Annual General Meeting (AGM). This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including the results of voting on resolutions. Although it contains voting results (which could relate to DVA), the context is the meeting itself and the resolutions voted upon, making AGM-R the most precise fit. The document is a formal announcement of the results, not just a proxy statement (PSI) or a general regulatory filing (RNS).
2021-11-23 English
Director Dealings
Director's Dealing Classification · 99% confidence The document explicitly states 'Director Dealings' in the title section and details a purchase of shares by Peter Jensen, the Non-Executive Chairman. The structure, including the RNS Number, date, and the detailed table format for 'Notification and public disclosure of transactions by persons discharging managerial responsibilities,' strongly indicates an insider transaction report. This directly corresponds to the definition for Director's Dealing (DIRS).
2021-11-11 English
Cheryl MacDiarmid appointed to Board of Directors
Board/Management Information Classification · 98% confidence The document is identified by the RNS Number and the header 'RNS Number : 3553Q', indicating it is a regulatory announcement distributed via the London Stock Exchange's RNS service. The content explicitly announces the appointment of a new Non-Executive Director to the Board of Directors, including biographical details and required disclosures under AIM Rules. This directly matches the definition for Board/Management Information (MANG). Although it is an RNS filing, the specific content is about management change, making MANG the most precise classification over the general RNS fallback.
2021-10-27 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1924 characters) and contains the header 'RNS Number : 1161Q' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, short-form regulatory market announcement rather than a comprehensive financial report (like 10-K or IR). Since it is a general regulatory announcement disseminated via the RNS system that doesn't fit into more specific categories like DIV, DIRS, or ER, the most appropriate classification is the general Regulatory Filings category.
2021-10-25 English
Allergy announces positive G309 results
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 0234Q' and is clearly identified as an announcement from Allergy Therapeutics plc, dated October 25, 2021. The content details positive top-line results from a clinical trial (G309) for a product (Grass MATA MPL), including statistical data, quotes from the CEO, and notes about future trials (G306 Phase III). This structure—announcing key results and operational updates via the RNS system—is characteristic of a general regulatory announcement or news release, rather than a comprehensive financial report (10-K, IR) or a dedicated earnings release (ER) which focuses strictly on financial metrics. Since it is a specific operational/clinical update distributed through the RNS system, and it doesn't fit the definitions for ER, CT, or specific financial reports, the most appropriate classification is the general regulatory announcement category, RNS.
2021-10-25 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.